Faricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict these outcomes; and obtain patient subjective experience on this new injection. This is a retrospective case review with clinical and imaging data from a tertiary referral unit (Birmingham and Midland Eye Centre, UK), involving patients who were switched to faricimab between 1 January and 1 December 2023. In all, 63 eyes (54 patients) with a mean age of 79.2 ± 7.8 and mean of 41.5 ± 22.4 previous anti-VEGF injections were analysed. With a mean of 4.81 ± 1.16 faricimab injections over 6.98 ± 1.75 months, post-treatment visual acuity was logMAR 0.49 ± 0.36 and central macular thickness (CMT) was 320.3 ± 97.9 µm. After first dose, 39.1% achieved complete dryness and 89.1% had anatomical improvement. Presence of subretinal fluid was a predictor of better functional outcomes (p = 0.001, β = −0.182), while initial CMT predicted better anatomical outcomes (p = 0.001, β = 0.688). Compared to their experiences of previous anti-VEGF injections, 89% of patients reported no more discomfort and 87.0% experienced no more floaters, photopsia, or bubbles post-injection. Faricimab switching has anatomical efficacy but limited functional improvement in treatment-refractory AMD. Patient experiences of faricimab compared to previous injections were overall positive.

Background. The coronavirus disease (COVID-19) is a highly contagious disease with profound health implications. It can affect any part of the body with variable severity. Various ophthalmic manifestations of coronavirus disease have been documented. Case Presentations. We reported three cases of outer retinopathies associated with COVID-19 infection. All three patients were young females. The first two patients presented within days of COVID-19 infection with complaints of black spots in the eyes. Multimodal retinal imaging showed lesions consistent with acute macular neuroretinopathy. Lesions were bilateral in the first patient and unilateral in the second one. Our third patient presented with blurred vision in one eye, 3 months after a suspected COVID-19 infection. Retinal imaging showed outer retinopathy. Our patients vision was good and maintained during the follow-up. All three were monitored on observation only, and symptoms and lesions improved with time. Conclusion. In conclusion, COVID-19-related thromboinflammatory response can result in localized vascular inflammation and hypoperfusion in any of the retinal capillary plexuses or choriocapillaris resulting in ischemia of the corresponding retinal or choroidal layers.

Introduction: Solar eclipses can cause solar retinopathy, but eclipse-related presentations may reflect public concern as well as true retinal injury. We evaluated the immediate ophthalmic service impact of the 12 August 2026 solar eclipse in the United Kingdom and characterised associated clinical, imaging, and online search findings. Methods: An observational case series was conducted at Birmingham and Midland Eye Centre, a tertiary eye casualty unit serving Birmingham and the wider West Midlands, England. Patients attending on 13 August 2026 with new visual symptoms or concern about ocular injury after viewing the Sun or eclipse were identified. Clinical characteristics, viewing behaviour, presenting and pinhole visual acuity, and multimodal retinal imaging findings were recorded, including optical coherence tomography, colour fundus photography, and fundus autofluorescence. Google Trends was used to assess contemporaneous UK online search interest in eclipse- and eye-related terms. Results: Of 128 eye casualty attendances on 13 August 2026, 10 (7.8%) were eclipse-related. Median age was 37.5 years, 7/10 (70%) patients were female, and 9/10 (90%) reported bilateral symptoms. Seven patients (70%) intentionally viewed the Sun or eclipse, and none reported confirmed use of certified eclipse glasses. Reduced or blurred vision was reported by 5/10 (50%) and photophobia by 4/10 (40%). Visual acuity was 6/9 or better in all 20 eyes and 6/6 or better in 17/20 (85%). Pinhole visual acuity was unchanged from presenting visual acuity in all 20 eyes. No clinically apparent macular abnormality or characteristic acute solar-retinopathy phenotype was identified. Google Trends showed a sharp, temporally concentrated increase in eclipse-related ocular searches around the eclipse, with several post-exposure queries showing marked increases or being classified as Breakout. Conclusions: The eclipse produced an immediate measurable burden on emergency ophthalmology services, with approximately 1 in 13 attendances on the following day being eclipse-related despite no definite acute solar retinopathy being identified. The accompanying increase in online search activity suggests substantial public concern with little demonstrable acute retinal pathology. As surveillance was restricted to the first full day after the eclipse, later presentations and longer-term symptom evolution cannot be excluded.